Dr Paul Connelly: Sex Steroids and Vascular Health

Portrait of Paul

Clinical Research Fellow Dr Paul Connelly is researching the effect of sex steroids upon vascular function and physiology. A deeper understanding of the alterations in vascular pathology and outcomes in transgender people receiving gender-affirming hormone therapy could be fundamental in informing the management of cardiovascular risk in this population and more broadly advance our understanding of the role of sex and gender in vascular health and disease.

We will undertake a series of studies to carefully assess vascular phenotypes, structure and function in people utilising gender-affirming hormone therapy, which will help us understand how sex hormones influence vascular health and impact risk of cardiovascular disease.

Supervisors:

Dr Stephen Dobbin: Markers and Mediators of Angiogenesis Inhibitor-Induced Vascular and Myocardial Toxicity

Image of Stephen dobbin

Clinical Research Fellow Dr Stephen Dobbin is undertaking a prospective study in patients with cancer. The outlook for patients with cancer has improved dramatically. This is mainly due to new drugs. Vascular Endothelial Growth Factor-signalling pathway inhibitors (VSPIs) are important anti-cancer drugs. However, they cause high blood pressure and can impair heart pumping. Patients are at risk of heart failure, heart attacks, strokes and kidney failure. Sometimes the VSPI dose needs to be reduced or treatment stopped as a result and these patients do not get full anti-cancer effects.

How VSPIs cause these side-effects is not well understood. Changes to small and large blood vessels seem very important. My project is using detailed heart and blood vessel scans, blood pressure monitoring and blood tests before and during treatment with VSPIs to monitor patients receiving these medications. This will allow better understanding of how VSPIs cause high blood pressure and heart pump problems. This should help to predict who will have these problems and to know the early warning signs. This will guide the best ways to treat and prevent these side-effects. We want patients with cancer to be able to get the best treatment without unacceptable heart and blood vessel side-effects or risks.

Supervisors:

Dr Leanne Mooney: Clonal Haematopoiesis Heart Failure

portrait of leanne mooney

Clinical Research Fellow Dr Leanne Mooney is investigating Age-Related Clonal Haematopoiesis and Inflammation in Patients with Heart Failure via a prospective cohort study. 

Supervisors: 

Dr Carly Adamson: Personalising Treatment of Heart Failure using Clinical Trial Data

Portrait of Carly

Clinical Research Fellow Dr Carly Adamson is looking at how we can use new statistical techniques to analyze information from patients with heart failure with the aim to help tailor care for each individual patient.

Supervisor:

Dr Su Ern Yeoh: Sodium glucose transporter inhibitor dapagliflozin versus thiazide diuretic in patients with heart failure and diuretic resistance

Clinical Research Fellow Dr Su Ern Yeoh is undertaking a multi-centre, open-label, randomised controlled clinical trial. Diuretic resistance in heart failure is difficult to treat. Current treatment guidelines for diuretic resistance involve a thiazide or thiazide-like diuretic or spironolactone in combination with a loop diuretic, but have limited efficacy in achieving adequate diuresis in these patients. Sodium glucose co-transporter-2 inhibitors (SGLT2i) have shown cardioprotective and renoprotective benefits, with a postulated role of glucose-mediated osmotic diuresis and natriuresis. Little is known about the therapeutic effect of SGLT2is in diuretic resistance. We aim to study if combination diuretic therapy with SGLT2i results in greater diuresis compared to combination diuretic therapy with thiazide diuretic in diuretic resistant heart failure patients.

Supervisors: 

Dr Michael Freeman: Understanding myocardial-scar interactions to predict ventricular arrhythmias

Portrait of Michael Freeman

Clinical Research Fellow Dr Michael Freeman is studying the interactions between scar after a heart attack and the development of dangerous abnormal heart rhythms. After a heart attack, scar in the heart muscle can disrupt the normal rhythm of the heart, putting patients at risk of collapse and sudden death. Some medications can reduce the risk bit the only way to prevent these deaths is to implant a device which can give a shock (a defibrillator). We would prefer a treatment which stopped these rhythms from happening in the first place. We know that the interaction between the scar and the heart muscle is crucial to determining when and how dangerous rhythms arise. Dr Freeman’s work will examine how this interaction could be tested objectively in patients to work out who is at high risk and why. We will look at the structure of the scar itself, but also the effect the scar has on the electrical activity. Through this we hope to develop better ways to identify those patients who really need a defibrillator and to improve treatments which modify scar-muscle interactions to reduce the occurrence of dangerous rhythms and so reduce the need for defibrillators. 

Supervisors: 

Dr Helen Casey: Acute insults and long-term consequences: Studies into endothelial cell function in cardiovascular diseases

portrait of Helen Casey Clinical Research Fellow Dr Helen Casey's PhD project is entitled "Acute insults and long-term consequences: Studies into endothelial cell function in cardiovascular diseases"

Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide. The vascular endothelium is a single-cell layer that lines blood vessels separating the blood and vascular smooth muscle. Endothelial function acts as an indicator of vascular health and dysfunction is seen as a precursor for CVD.

Acute insults such as sepsis, pre-eclampsia and COVID-19 which resolve are thought to be linked with increased future risk of CVD. We aim to explore the role these acute insults have on endothelial function and whether any lasting dysfunction exists predisposing to CVD risk.

Cardiovascular risk differs between the sexes. Women have a lower risk for developing CVD than age-matched men until the menopause, where thereafter they develop an accelerated phenotype resulting in a rapid rise in the prevalence and mortality related to CVD. This effect is thought to be mediated, in part, through oestrogens effects on endothelial function.

We aim to explore the impact of sex steroids and gender on endothelial function and how this interacts with acute and possible lasting dysfunction.

Supervisors:

Dr Richard McFarlane: Translational Medical Science for Therapy Development in Small Vessel Disease

selfie of Richard McFarlane

More information on Richard's PhD project is coming soon. 

Supervisors:

  • Professor Colin Berry

Publications

Sattar, N. , Welsh, P. , Leslie, W. S., Thom, G. , McCombie, L., Brosnahan, N. , Richardson, J., Gill, J. M. R. , Crawford, L. and Lean, M. E. J. (2023) Dietary weight-management for type 2 diabetes remissions in South Asians: the South Asian diabetes remission randomised trial for proof-of-concept and feasibility (STANDby). Lancet Regional Health – Southeast Asia, 9, 100111. (doi: 10.1016/j.lansea.2022.100111)

McErlane, J., McCall, P. , Willder, J., Berry, C. and Shelley, B. (2022) Right ventricular free wall longitudinal strain is independently associated with mortality in mechanically ventilated patients with COVID-19. Annals of Intensive Care, 12(1), 104. (doi: 10.1186/s13613-022-01077-7) (PMID:36370220)

Mayne, K. J., Lees, J. S. , Rutherford, E., Thomson, P. C., Traynor, J. P., Dey, V. , Lang, N. N. and Mark, P. B. (2022) Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios: associations with mortality in a haemodialysis cohort. Clinical Kidney Journal, (Accepted for Publication)

Kondo, T. et al. (2022) Predicting stroke in heart failure and reduced ejection fraction without atrial fibrillation. European Heart Journal, 43(42), pp. 4469-4479. (doi: 10.1093/eurheartj/ehac487) (PMID:36017729) (PMCID:PMC9637422)

Yang, M. et al. (2022) Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan. European Journal of Heart Failure, (doi: 10.1002/ejhf.2722) (PMID:36342375) (Early Online Publication)

Wang, X. et al. (2022) Sex differences in characteristics, outcomes and treatment response with dapagliflozin across the range of ejection fraction in patients with heart failure: insights from DAPA-HF and DELIVER. Circulation, (doi: 10.1161/circulationaha.122.062832) (PMID:36342789) (Early Online Publication)

Kalra, P. R. et al. (2022) Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet, (doi: 10.1016/S0140-6736(22)02083-9) (In Press)

Adamson, C. et al. (2022) Dapagliflozin for heart failure according to body mass index: the DELIVER trial. European Heart Journal, 43(41), pp. 4406-4417. (doi: 10.1093/eurheartj/ehac481) (PMID:36029309) (PMCID:PMC9622300)

Butt, J. H. et al. (2022) Dapagliflozin, atrial fibrillation, and heart failure with mildly reduced or preserved ejection fraction in DELIVER. Journal of the American College of Cardiology, 80(18), pp. 1705-1717. (doi: 10.1016/j.jacc.2022.08.718) (PMID:36041668)

Lees, J. S. , Dobbin, S. J.H. , Elyan, B. M.P., Gilmour, D. F., Tomlinson, L. P., Lang, N. N. and Mark, P. B. (2022) A systematic review and meta-analysis of the effect of intravitreal VEGF inhibitors on cardiorenal outcomes. Nephrology Dialysis Transplantation, (doi: 10.1093/ndt/gfac305) (PMID:36318455) (Early Online Publication)

Mary, S. , Boder, P., Padmanabhan, S. , McBride, M. W. , Graham, D. , Delles, C. and Dominiczak, A. F. (2022) The role of uromodulin in salt-sensitive hypertension. Hypertension, 79, pp. 2419-2429. (doi: 10.1161/HYPERTENSIONAHA.122.19888)

Kondo, T. et al. (2022) Prognosis in patients with cardiogenic shock who received temporary mechanical circulatory support. JACC: Asia, (doi: 10.1016/j.jacasi.2022.10.004) (In Press)

Garimella, P. S., Du Toit, C., Le, N. N. and Padmanabhan, S. (2022) A genomic deep field view of hypertension. Kidney International, (doi: 10.1016/j.kint.2022.09.029) (Early Online Publication)

Lim, M. W.S., Setjiadi, D., Dobbin, S. J.H., Lang, N. N. , Delles, C. and Connelly, P. J. (2022) Nailfold video-capillaroscopy in the study of cardiovascular disease: a systematic review. Blood Pressure Monitoring, (doi: 10.1097/MBP.0000000000000624) (PMID:36281701) (Early Online Publication)

Butt, J. H. et al. (2022) Efficacy and safety of dapagliflozin according to frailty in patients with heart failure: a prespecified analysis of the DELIVER trial. Circulation, 146(16), pp. 1210-1224. (doi: 10.1161/CIRCULATIONAHA.122.061754) (PMID:36029465)

Berry, C. and Kunadian, V. (2022) Computed tomography coronary angiography should be the initial diagnostic test in suspected angina. European Heart Journal, (Accepted for Publication)

Main, A. et al. (2022) Dynamic but discordant alterations in zDHHC5 expression and palmitoylation of its substrates in cardiac pathologies. Frontiers in Physiology, 13, 1023237. (doi: 10.3389/fphys.2022.1023237)

Berry, C. , Morrow, A. J. , Marzilli, M. and Pepine, C. J. (2022) What is the role of assessing ischemia to optimize therapy and outcomes for patients with stable angina and non-obstructed coronary arteries? Cardiovascular Drugs and Therapy, 36(5), pp. 1027-1038. (doi: 10.1007/s10557-021-07179-x) (PMID:33978865) (PMCID:PMC9519699)

Ferreira, J. P., Claggett, B. L., Docherty, K. F. , Jhund, P. S. , Zannad, F., Solomon, S. D. and McMurray, J. J.V. (2022) Within trial comparison of survival time projections from short-term follow-up with long-term follow-up findings. ESC Heart Failure, 9(5), pp. 3655-3658. (doi: 10.1002/ehf2.13731) (PMID:35799450)

Dubé, M.‐P. et al. (2022) Pharmacogenomic study of heart failure and candesartan response from the CHARM programme. ESC Heart Failure, 9(5), pp. 2997-3008. (doi: 10.1002/ehf2.14026) (PMID:35736394)

Kazmi, S., Kambhampati, C., Cleland, J. G.F. , Cuthbert, J., Kazmi, K. S., Pellicori, P. , Rigby, A. S. and Clark, A. L. (2022) Dynamic risk stratification using Markov chain modelling in patients with chronic heart failure. ESC Heart Failure, 9(5), pp. 3009-3018. (doi: 10.1002/ehf2.14028) (PMID:35736536)

Welsh, P. et al. (2022) Reference ranges for NT-proBNP (N-terminal pro-B-type natriuretic peptide) and risk factors for higher NT-proBNP concentrations in a large general population cohort. Circulation: Heart Failure, 15(10), pp. 957-967. (doi: 10.1161/CIRCHEARTFAILURE.121.009427) (PMID:36098049) (PMCID:PMC9561238)

Adamson, C. et al. (2022) Liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA-HF. European Journal of Heart Failure, 24(10), pp. 1856-1868. (doi: 10.1002/ejhf.2649) (PMID:36054568)

Louca, P., Tran, T. Q. B., Toit, C. d., Christofidou, P., Spector, T. D., Mangino, M., Suhre, K., Padmanabhan, S. and Menni, C. (2022) Machine learning integration of multimodal data identifies key features of blood pressure regulation. EBioMedicine, 84, 104243. (doi: 10.1016/j.ebiom.2022.104243) (PMID:36084617) (PMCID:PMC9463529)

Docherty, K. F. et al. (2022) Iron deficiency in heart failure and effect of dapagliflozin: findings from DAPA-HF. Circulation, 146(13), pp. 980-994. (doi: 10.1161/CIRCULATIONAHA.122.060511) (PMID:35971840) (PMCID:PMC9508991)

Tabák, A. G., Brunner, E. J., Lindbohm, J. V., Singh-Manoux, A., Shipley, M. J., Sattar, N. and Kivimäki, M. (2022) Risk of macrovascular and microvascular disease in diabetes diagnosed using oral glucose tolerance test with and without confirmation by hemoglobin A1c: the Whitehall II cohort study. Circulation, 146(13), pp. 995-1005. (doi: 10.1161/CIRCULATIONAHA.122.059430) (PMID:36004644)

Pellicori, P. , Kalra, P. R., Clark, A. L., Friday, J. M. and Cleland, J. G. F. (2022) CKD and CKD-ism in heart failure – what a mess! European Journal of Heart Failure, (doi: 10.1002/ejhf.2696) (Early Online Publication)

Butt, J. H. et al. (2022) Sacubitril/valsartan and frailty in patients with heart failure and preserved ejection fraction. Journal of the American College of Cardiology, 80(12), pp. 1130-1143. (doi: 10.1016/j.jacc.2022.06.037) (PMID:36050227)

Conrad, N., Verbeke, G., Molenberghs, G., Goetschalckx, L., Callender, T., Cambridge, G., Mason, J. C., Rahimi, K., McMurray, J. J.V. and Verbakel, J. Y. (2022) Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK. Lancet, 400(10354), (doi: 10.1016/S0140-6736(22)01349-6) (PMID:36041475)

Butt, J. H. and McMurray, J. J.V. (2022) Vericiguat, sacubitril/valsartan and more evidence that we are failing our patients. European Journal of Heart Failure, 24(9), pp. 1623-1624. (doi: 10.1002/ejhf.2647) (PMID:35919944)

Nazarzadeh, M. et al. (2022) Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis. Lancet Diabetes and Endocrinology, 10(9), pp. 645-654. (doi: 10.1016/S2213-8587(22)00172-3) (PMID:35878651)

Gao, X. et al. (2022) Palmitoylation regulates cellular distribution of and transmembrane Ca flux through TrpM7. Cell Calcium, 106, 102639. (doi: 10.1016/j.ceca.2022.102639) (PMID:36027648)

Jhund, P. S. et al. (2022) Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nature Medicine, 28(9), pp. 1956-1964. (doi: 10.1038/s41591-022-01971-4) (PMID:36030328) (PMCID:PMC9499855)

Stables, R. H. et al. (2022) Routine pressure wire assessment versus conventional angiography in the management of patients with coronary artery disease: the RIPCORD 2 trial. Circulation, 146(9), pp. 687-698. (doi: 10.1161/CIRCULATIONAHA.121.057793) (PMID:35946404)

Zannad, F. et al. (2022) Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights from the EMPEROR program. European Heart Journal, (doi: 10.1093/eurheartj/ehac495) (PMID:36017745) (Early Online Publication)

de Wit, S., Glen, C., de Boer, R. A. and Lang, N. N. (2022) Mechanisms shared between cancer, heart failure, and targeted anti-cancer therapies. Cardiovascular Research, (doi: 10.1093/cvr/cvac132) (PMID:36004495) (Early Online Publication)

Welsh, P. , Kimenai, D. M., Marioni, R. E., Hayward, C., Campbell, A., Porteous, D., Mills, N. L., O’Rahilly, S. and Sattar, N. (2022) Reference ranges for GDF-15, and risk factors associated with GDF-15, in a large general population cohort. Clinical Chemistry and Laboratory Medicine, (doi: 10.1515/cclm-2022-0135) (PMID:35976089)

Kalra, P. R. et al. (2022) Rationale and design of a randomised trial of intravenous iron in patients with heart failure. Heart, (doi: 10.1136/heartjnl-2022-321304) (PMID:35948408) (Early Online Publication)

Adamson, C. et al. (2022) Initial decline ("dip") in estimated glomerular filtration rate following initiation of dapagliflozin in patients with heart failure and reduced ejection fraction: insights from DAPA-HF. Circulation, 146(6), pp. 438-449. (doi: 10.1161/CIRCULATIONAHA.121.058910) (PMID:35442064) (PMCID:PMC9354593)

Hoes, M. F., Arany, Z., Bauersachs, J., Hilfiker-Kleiner, D., Petrie, M. C. , Sliwa, K. and van der Meer, P. (2022) Pathophysiology and risk factors of peripartum cardiomyopathy. Nature Reviews Cardiology, 19(8), pp. 555-565. (doi: 10.1038/s41569-021-00664-8) (PMID:35017720)

Butt, J. H. et al. (2022) Effects of dapagliflozin according to the heart failure collaboratory medical therapy score insights from DAPA-HF. JACC: Heart Failure, 10(8), pp. 543-555. (doi: 10.1016/j.jchf.2022.03.009) (PMID:35902157)

Lip, S., Dempster, G., Jain, S., Brooksbank, K., Ghouri, N. , McCallum, L. and Padmanabhan, S. (2022) Underrepresentation of ethnic minorities in hypertension research—a survey of enablers and barriers among South Asian and African communities in Glasgow. Trials, 23, 609. (doi: 10.1186/s13063-022-06542-z) (PMID:35906700) (PMCID:PMC9335986)

Lee, M. M.Y. et al. (2022) Effect of empagliflozin on kidney biochemical and imaging outcomes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation, 146(4), pp. 364-367. (doi: 10.1161/CIRCULATIONAHA.122.059851) (PMID:35877829)

Rios, F. J. et al. (2022) TRPM7 deficiency exacerbates cardiovascular and renal damage induced by aldosterone-salt. Communications Biology, 5, 746. (doi: 10.1038/s42003-022-03715-z) (PMID:35882956) (PMCID:PMC9325869)

Cowie, M. and Cleland, J. G.F. (2022) The COVID-19 pandemic and heart failure: lessons from GUIDE-HF. European Heart Journal, 43(27), pp. 2619-2621. (doi: 10.1093/eurheartj/ehac226) (PMID:35511076)

Shen, L. et al. (2022) Accelerated and personalized therapy for heart failure with reduced ejection fraction. European Heart Journal, 43(27), pp. 2573-2587. (doi: 10.1093/eurheartj/ehac210) (PMID:35467706)

Sattar, N. , McGuire, D. K. and Gill, J. M.R. (2022) High circulating triglycerides are most commonly a marker of ectopic fat accumulation: connecting the clues to advance lifestyle interventions. Circulation, 146(2), pp. 77-79. (doi: 10.1161/CIRCULATIONAHA.122.060411) (PMID:35858157)

Rao, S., Li, Y., Ramakrishnan, R., Hassaine, A., Canoy, D., Cleland, J. G. , Lukasiewicz, T., Salimi-Khorshidi, G. and Rahimi, K. (2022) An explainable transformer-based deep learning model for the prediction of incident heart failure. IEEE Journal of Biomedical and Health Informatics, 26(7), pp. 3362-3372. (doi: 10.1109/JBHI.2022.3148820) (PMID:35130176)

Gallacher, P. J. et al. (2022) High-sensitivity cardiac troponin and the diagnosis of myocardial infarction in patients with renal impairment. Kidney International, 102(1), pp. 149-159. (doi: 10.1016/j.kint.2022.02.019) (PMID:35271932)

Le, N. N., Tran, T. Q. B., Lip, S., McCallum, L., McClure, J. , Dominiczak, A. F. , Gill, D. and Padmanabhan, S. (2022) Unravelling the distinct effects of systolic and diastolic blood pressure using Mendelian randomisation. Genes, 13(7), 1226. (doi: 10.3390/genes13071226) (PMID:35886009) (PMCID:PMC9323763)

Henriksen, P. A. et al. (2022) Rationale and design of the Cardiac CARE trial: A randomized trial of troponin-guided neurohormonal blockade for the prevention of anthracycline cardiotoxicity. Circulation: Heart Failure, 15(7), e009445. (doi: 10.1161/CIRCHEARTFAILURE.121.009445) (PMID:35766037)

Ang, D. and Berry, C. (2022) FAVOR III China: quantitative flow ratio-guided coronary intervention in practice. Cardiovascular Research, 118(11), e78-e80. (doi: 10.1093/cvr/cvac109) (PMID:36000975)

Lip, S., McCallum, L., Delles, C. , McClure, J. D. , Guzik, T., Berry, C. , Touyz, R. and Padmanabhan, S. (2022) Rationale and design for the LOnger-term effects of SARS-CoV-2 INfection on blood Vessels And blood pRessure (LOCHINVAR). Open Heart, 9(1), e002057. (doi: 10.1136/openhrt-2022-002057) (PMID:35750422) (PMCID:PMC9234432)

Wijkman, M. O. et al. (2022) Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials. Cardiovascular Diabetology, 21, 110. (doi: 10.1186/s12933-022-01545-1) (PMID:35717169) (PMCID:PMC9206286)

Bomer, N., Pavez-Giani, M. G., Grote Beverborg, N., Cleland, J. G.F. , van Veldhuisen, D. J. and van der Meer, P. (2022) Micronutrient deficiencies in heart failure: mitochondrial dysfunction as a common pathophysiological mechanism? Journal of Internal Medicine, 291(6), pp. 713-731. (doi: 10.1111/joim.13456) (PMID:35137472) (PMCID:PMC9303299)

McDowell, K. et al. (2022) Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF. European Journal of Heart Failure, 24(6), pp. 1066-1076. (doi: 10.1002/ejhf.2433) (PMID:35064721)

Halliday, B. P. et al. (2022) Changes in clinical and imaging variables during withdrawal of heart failure therapy in recovered dilated cardiomyopathy. ESC Heart Failure, 9(3), pp. 1616-1624. (doi: 10.1002/ehf2.13872) (PMID:35257498) (PMCID:PMC9065828)

Connelly, P. J. , Currie, G. and Delles, C. (2022) Sex differences in the prevalence, outcomes and management of hypertension. Current Hypertension Reports, 24(6), pp. 185-192. (doi: 10.1007/s11906-022-01183-8) (PMID:35254589) (PMCID:PMC9239955)

Rastogi, T. et al. (2022) Comparing and contrasting risk factors for heart failure in patients with and without history of myocardial infarction: data from HOMAGE and the UK Biobank. European Journal of Heart Failure, 24(6), pp. 976-984. (doi: 10.1002/ejhf.2495) (PMID:35365899)

Wang, Y. et al. (2022) Associations of long-term visit-to-visit blood pressure variability with subclinical kidney damage and albuminuria in adulthood: a 30-year prospective cohort study. Hypertension, 79(6), pp. 1247-1256. (doi: 10.1161/HYPERTENSIONAHA.121.18658) (PMID:35360932) (PMCID:PMC9093226)

Ho, F. K. et al. (2022) Association of gamma-glutamyltransferase levels with total mortality, liver-related, and cardiovascular outcomes: a prospective cohort study in the UK Biobank. EClinicalMedicine, 48, 101435. (doi: 10.1016/j.eclinm.2022.101435) (PMID:35706481) (PMCID:PMC9112033)

Cleland, J. G.F. et al. (2022) The effect of cardiac resynchronization without a defibrillator on morbidity and mortality: an individual-patient-data meta-analysis of COMPANION and CARE-HF. European Journal of Heart Failure, 24(6), pp. 1080-1090. (doi: 10.1002/ejhf.2524) (PMID:35490339)

Butt, J. H. et al. (2022) Efficacy and safety of dapagliflozin according to frailty in heart failure with reduced ejection fraction. Annals of Internal Medicine, 175(6), pp. 820-830. (doi: 10.7326/m21-4776) (PMID:35467935)

Morrow, A. J. et al. (2022) A multisystem, cardio-renal investigation of post-COVID-19 illness. Nature Medicine, 28(6), pp. 1303-1313. (doi: 10.1038/s41591-022-01837-9) (PMID:35606551) (PMCID:PMC9205780)

Lucas-Herald, A. K. and Delles, C. (2022) Carotid intima-media thickness is associated with obesity and hypertension in young people. Hypertension, 79(6), pp. 1177-1179. (doi: 10.1161/hypertensionaha.122.19163) (PMID:35544586)

Schwartze, J. T., Havenga, M., Bakker, W. A. M., Bradshaw, A. C. and Nicklin, S. A. (2022) Adenoviral vectors for cardiovascular gene therapy applications: a clinical and industry perspective. Journal of Molecular Medicine, 100(6), pp. 875-901. (doi: 10.1007/s00109-022-02208-0) (PMID:35606652) (PMCID:PMC9126699)

Borlaug, B. A. et al. (2022) Latent pulmonary vascular disease may alter the response to therapeutic atrial shunt device in heart failure. Circulation, 145(21), pp. 1592-1604. (doi: 10.1161/CIRCULATIONAHA.122.059486) (PMID:35354306) (PMCID:PMC9133195)

Udell, J. A., Jones, W. S., Petrie, M. C. , Harrington, J., Anker, S. D., Bhatt, D. L., Hernandez, A. F. and Butler, J. (2022) Sodium glucose cotransporter-2 inhibition for acute myocardial infarction: JACC Review Topic of the Week. Journal of the American College of Cardiology, 79(20), pp. 2058-2068. (doi: 10.1016/j.jacc.2022.03.353) (PMID:35589167) (PMCID:PMC8972442)

Lucas-Herald, A. K. et al. (2022) Vascular dysfunction and increased cardiovascular risk in hypospadias. European Heart Journal, 43(19), pp. 1832-1845. (doi: 10.1093/eurheartj/ehac112) (PMID:35567552) (PMCID:PMC9113289)

Sattar, N. and Welsh, P. (2022) Risk scoring in secondary prevention: a basis for informed clinical decisions in the context of ever-expanding treatments. European Heart Journal, 43(18), pp. 1728-1730. (doi: 10.1093/eurheartj/ehac125) (PMID:35265991)

Graham, F. J., Masini, G., Pellicori, P. , Cleland, J. G.F. , Greenlaw, N., Friday, J., Kazmi, S. and Clark, A. L. (2022) Natural history and prognostic significance of iron deficiency and anaemia in ambulatory patients with chronic heart failure. European Journal of Heart Failure, 24(5), pp. 807-817. (doi: 10.1002/ejhf.2251) (PMID:34050582)

Rossitto, G. and Delles, C. (2022) Does excess tissue sodium storage regulate blood pressure? Current Hypertension Reports, 24(5), pp. 115-122. (doi: 10.1007/s11906-022-01180-x) (PMID:35192140) (PMCID:PMC9142429)

Butt, J. H., Adamson, C., Docherty, K. F. , Vaduganathan, M., Solomon, S. D., Anand, I. S., Zannad, F., Køber, L., Jhund, P. S. and McMurray, J. J.V. (2022) Eligibility for pharmacological therapies in heart failure with reduced ejection fraction: implications of the new CKD-EPI creatinine equation for estimating glomerular filtration rate. European Journal of Heart Failure, 24(5), pp. 861-866. (doi: 10.1002/ejhf.2460) (PMID:35199418)

Halliday, B. P. and Cleland, J. G. F. (2022) Maintaining success for patients with dilated cardiomyopathy and remission of heart failure. JACC: Basic to Translational Science, 7(5), pp. 500-503. (doi: 10.1016/j.jacbts.2022.03.008) (PMID:35663636) (PMCID:PMC9156436)

Holman, N. , Wild, S. H., Khunti, K., Knighton, P., O'Keefe, J., Bakhai, C., Young, B., Sattar, N. , Valabhji, J. and Gregg, E. W. (2022) Incidence and characteristics of remission of type 2 diabetes in England: a cohort study using the National Diabetes Audit. Diabetes Care, 45(5), pp. 1151-1161. (doi: 10.2337/dc21-2136) (PMID:35320360) (PMCID:PMC9174970)

Yeoh, S. E. et al. (2022) Relationship of dapagliflozin with serum sodium: findings from the DAPA-HF trial. JACC: Heart Failure, 10(5), pp. 306-318. (doi: 10.1016/j.jchf.2022.01.019) (PMID:35483792)

Mirabito Colafella, K. M. et al. (2022) Differential effects of cyclo-oxygenase 1 and 2 inhibition on angiogenesis inhibitor-induced hypertension and kidney damage. Clinical Science, 136(9), pp. 675-694. (doi: 10.1042/CS20220182) (PMID:35441670) (PMCID:PMC9093150)

Maurovich-Horvat, P. et al. (2022) CT or invasive coronary angiography in stable chest pain. New England Journal of Medicine, 386(17), pp. 1591-1602. (doi: 10.1056/NEJMoa2200963) (PMID:35240010)

Sani, R. N., Connelly, P. J. , Toft, M., Rowa-Dewar, N., Delles, C. , Gasevic, D. and Karaye, K. M. (2022) Rural-urban difference in the prevalence of hypertension in West Africa: a systematic review and meta-analysis. Journal of Human Hypertension, (doi: 10.1038/s41371-022-00688-8) (PMID:35430612) (Early Online Publication)

Camargo, L. L. et al. (2022) Central role of c-Src in NOX5- mediated redox signaling in vascular smooth muscle cells in human hypertension. Cardiovascular Research, 118(5), pp. 1359-1373. (doi: 10.1093/cvr/cvab171) (PMID:34320175) (PMCID:PMC8953456)

Cleland, J. G.F. , Butler, J., Januzzi, J. L., Pellicori, P. and McDonagh, T. (2022) Only people with increased plasma concentrations of natriuretic peptides should be included in outcome trials of diabetes, cardiovascular and kidney disease: implications for clinical practice. European Journal of Heart Failure, 24(4), pp. 678-680. (doi: 10.1002/ejhf.2488) (PMID:35297132)

Docherty, K. F. et al. (2022) Effects of dapagliflozin in Asian patients with heart failure and reduced ejection fraction in DAPA-HF. JACC: Asia, 2(2), pp. 139-153. (doi: 10.1016/j.jacasi.2022.02.004)

Neves, K. B. , Rios, F. J. , Sevilla-Montero, J., Montezano, A. C. and Touyz, R. M. (2022) Exosomes and the cardiovascular system: role in cardiovascular health and disease. Journal of Physiology, (doi: 10.1113/JP282054) (PMID:35306667) (Early Online Publication)

Lee, M. M.Y. et al. (2022) Renin–angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysis. European Heart Journal: Cardiovascular Pharmacotherapy, 8(2), pp. 165-178. (doi: 10.1093/ehjcvp/pvaa138) (PMID:33337478) (PMCID:PMC7799280)

Martin, T. P. , MacDonald, E. A., Elbassioni, A. A., Zaeri, A. A. I., O'Toole, D., Nicklin, S. A. , Gray, G. A. and Loughrey, C. M. (2022) Pre-clinical models of myocardial infarction: from mechanism to translation. British Journal of Pharmacology, 179(5), pp. 770-791. (doi: 10.1111/bph.15595) (PMID:34131903)

Yeoh, S. E., Dewan, P. , Serenelli, M., Ferreira, J. P., Pitt, B., Swedberg, K., Veldhuisen, D. J., Zannad, F., Jhund, P. S. and McMurray, J. J.V. (2022) Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS-HF and RALES. European Journal of Heart Failure, 24(3), pp. 529-538. (doi: 10.1002/ejhf.2350) (PMID:34536265)

Butt, J. H. et al. (2022) Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF. European Journal of Heart Failure, 24(3), pp. 513-525. (doi: 10.1002/ejhf.2381) (PMID:34766424)

Curtain, J. P. et al. (2022) Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF. European Journal of Heart Failure, 24(3), pp. 551-561. (doi: 10.1002/ejhf.2419) (PMID:34969175)

Glen, C., Tan, Y. Y., Waterston, A., Evans, T. R. J. , Jones, R. J. , Petrie, M. C. and Lang, N. N. (2022) Mechanistic and clinical overview cardiovascular toxicity of BRAF and MEK inhibitors: JACC: CardioOncology state-of-the-art review. JACC: CardioOncology, 4(1), pp. 1-18. (doi: 10.1016/j.jaccao.2022.01.096) (PMID:35492830) (PMCID:PMC9040125)

Jackson, A. M. et al. (2022) Diabetes and pre‐diabetes in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure, 24(3), pp. 497-509. (doi: 10.1002/ejhf.2403) (PMID:34918855)

Sattar, N. , McGuire, D. K., Pavo, I., Weerakkody, G. J., Nishiyama, H., Wiese, R. J. and Zoungas, S. (2022) Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nature Medicine, 28(3), pp. 591-598. (doi: 10.1038/s41591-022-01707-4) (PMID:35210595) (PMCID:PMC8938269)

Reynolds, H. R., Bairey Merz, C. N., Berry, C. , Samuel, R., Saw, J., Smilowitz, N. R., de Souza, A. C. d. A.H., Sykes, R. , Taqueti, V. R. and Wei, J. (2022) Coronary arterial function and disease in women with no obstructive coronary arteries. Circulation Research, 130(4), pp. 529-551. (doi: 10.1161/CIRCRESAHA.121.319892) (PMID:35175840) (PMCID:PMC8911308)

Nogal, A. et al. (2022) Incremental value of a panel of serum metabolites for predicting risk of atherosclerotic cardiovascular disease. Journal of the American Heart Association, 11(4), e024590. (doi: 10.1161/JAHA.121.024590) (PMID:35156414) (PMCID:PMC9245800)

Adamson, C. and Jhund, P. S. (2022) Bringing FIDELITY to the estimate of treatment effects of finerenone in chronic kidney disease due to type 2 diabetes. European Heart Journal, 43(6), pp. 485-487. (doi: 10.1093/eurheartj/ehab827) (PMID:34888636)

Masini, G., Graham, F. J., Pellicori, P. , Cleland, J. G.F. , Cuthbert, J. J., Kazmi, S., Inciardi, R. M. and Clark, A. L. (2022) Criteria for iron deficiency in patients with heart failure. Journal of the American College of Cardiology, 79(4), pp. 341-351. (doi: 10.1016/j.jacc.2021.11.039) (PMID:35086656)

Kondo, T. and McMurray, J. J.V. (2022) Re-emergence of heart failure with a normal ejection fraction? European Heart Journal, 43(5), pp. 427-429. (doi: 10.1093/eurheartj/ehab828) (PMID:34878520)

Main, A. and Fuller, W. (2022) Protein S‐palmitoylation: advances and challenges in studying a therapeutically important lipid modification. FEBS Journal, 289(4), pp. 861-882. (doi: 10.1111/febs.15781) (PMID:33624421)

Docherty, K. F. and Petrie, M. C. (2022) Sodium-glucose cotransporter 2 inhibitors as a treatment for heart failure. Heart, 108(4), pp. 312-320. (doi: 10.1136/heartjnl-2020-318658) (PMID:34127540)

Connelly, P. J. , Casey, H., Montezano, A. C., Touyz, R. M. and Delles, C. (2022) Sex steroids receptors, hypertension and vascular ageing. Journal of Human Hypertension, 36(2), pp. 120-125. (doi: 10.1038/s41371-021-00576-7) (PMID:34230581) (PMCID:PMC8850193)

Ravassa, S. et al. (2022) Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial. European Journal of Heart Failure, 24(2), pp. 321-331. (doi: 10.1002/ejhf.2394) (PMID:34841615)

Delles, C. (2022) Maternally inherited essential hypertension: adding further complexity to an already complex condition. American Journal of Hypertension, 35(1), pp. 16-18. (doi: 10.1093/ajh/hpab133) (PMID:34427578) (PMCID:PMC8730502)

Lee, M. M.Y. , Kristensen, S. L., Gerstein, H. C., McMurray, J. J.V. and Sattar, N. (2022) Cardiovascular and mortality outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a meta-analysis with the FREEDOM cardiovascular outcomes trial. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 16(1), 102382. (doi: 10.1016/j.dsx.2021.102382) (PMID:35030451)

Delles, C. and Rossitto, G. (2022) Of snails, earthworms, and men: insights into strategies to preserve water. Function, 3(1), zqab071. (doi: 10.1093/function/zqab071) (PMID:35330922) (PMCID:PMC8788808)

Morrow, A. et al. (2022) Prevention and early treatment of the long-term physical effects of COVID-19 in adults: design of a randomised controlled trial of resistance exercise—CISCO-21. Trials, 23, 660. (doi: 10.1186/s13063-022-06632-y)

Kondo, T., Adachi, T., Koba, K., Okumura, T., Izawa, H., Murohara, T., McMurray, J. J.V. and Yamada, S. (2022) Physical frailty and use of guideline-recommended drugs in patients with heart failure and reduced ejection fraction. Journal of the American Heart Association, (Accepted for Publication)

Mooney, L. et al. (2021) Impact of chronic obstructive pulmonary disease in patients with heart failure with preserved ejection fraction: insights from PARAGON‐HF. Journal of the American Heart Association, 10(23), e021494. (doi: 10.1161/JAHA.121.021494) (PMID:34796742) (PMCID:PMC9075384)

Petrie, M. C. et al. (2021) High-dose intravenous iron reduces myocardial infarction in patients on haemodialysis. Cardiovascular Research, (doi: 10.1093/cvr/cvab317) (PMID:34875022) (Early Online Publication)

Collison, D. et al. (2021) Post-stenting fractional flow reserve vs coronary angiography for optimization of percutaneous coronary intervention (TARGET-FFR). European Heart Journal, 42(45), pp. 4656-4668. (doi: 10.1093/eurheartj/ehab449) (PMID:34279606)

Connelly, P. J. and Delles, C. (2021) Cardiovascular disease in transgender people: recent research and emerging evidence. Cardiovascular Research, 117(14), e174-e176. (doi: 10.1093/cvr/cvab288) (PMID:34568899) (PMCID:PMC8683701)

Welsh, P. et al. (2021) Lipoprotein(a) and cardiovascular disease: prediction, attributable risk fraction and estimating benefits from novel interventions. European Journal of Preventive Cardiology, 28(18), pp. 1991-2000. (doi: 10.1093/eurjpc/zwaa063) (PMID:33624048)

Jackson, A. M. et al. (2021) Hypertensive disorders in women with peripartum cardiomyopathy: insights from the ESC EORP PPCM Registry. European Journal of Heart Failure, 23(12), pp. 2058-2069. (doi: 10.1002/ejhf.2264) (PMID:34114268)

Holman, N. et al. (2021) Completion of annual diabetes care processes and mortality: a cohort study using the National Diabetes Audit for England and Wales. Diabetes, Obesity and Metabolism, 23(12), pp. 2728-2740. (doi: 10.1111/dom.14528) (PMID:34405512)

Lumbers, R. T. et al. (2021) The genomics of heart failure: design and rationale of the HERMES consortium. ESC Heart Failure, 8(6), pp. 5531-5541. (doi: 10.1002/ehf2.13517) (PMID:34480422) (PMCID:PMC8712846)

Lang, N. N. and Touyz, R. M. (2021) Mechanistic science in cardiovascular-oncology: the way forward to maximise anti-cancer drug effects and minimise cardiovascular toxicity. Clinical Science, 135(23), pp. 2661-2663. (doi: 10.1042/CS20210986) (PMID:34881389) (PMCID:PMC8672202)

Mary, S. , Boder, P., Rossitto, G., Graham, L., Scott, K., Flynn, A., Kipgen, D., Graham, D. and Delles, C. (2021) Salt loading decreases urinary excretion and increases intracellular accumulation of uromodulin in stroke-prone spontaneously hypertensive rats. Clinical Science, 135(24), pp. 2749-2761. (doi: 10.1042/CS20211017) (PMID:34870708) (PMCID:PMC8689196)

Butt, J. H. et al. (2021) Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide: insights from the DAPA-HF trial. Circulation: Heart Failure, 14(12), e008837. (doi: 10.1161/CIRCHEARTFAILURE.121.008837) (PMID:34802253)

Rankin, A. J. et al. (2021) Myocardial changes on 3T cardiovascular magnetic resonance imaging in response to haemodialysis with fluid removal. Journal of Cardiovascular Magnetic Resonance, 23, 125. (doi: 10.1186/s12968-021-00822-4) (PMCID:PMC8580743)

Ghouri, N. , Javed, H. and Sattar, N. (2021) Pharmacological management of diabetes for reducing glucose levels and cardiovascular disease risk: what evidence in South Asians? Current Diabetes Reviews, 17(9), e122820189511. (doi: 10.2174/1573399817666201228120725) (PMID:33371853)

He, T. et al. (2021) Urinary peptides in heart failure: a link to molecular pathophysiology. European Journal of Heart Failure, 23(11), pp. 1875-1887. (doi: 10.1002/ejhf.2195) (PMID:33881206)

Docherty, K. F. et al. (2021) Extrapolating long-term event-free and overall survival with dapagliflozin in patients with heart failure and reduced ejection fraction: an exploratory analysis of a phase 3 randomized clinical trial. JAMA Cardiology, 6(11), pp. 1298-1305. (doi: 10.1001/jamacardio.2021.2632) (PMID:34319398)

Cuthbert, J. J., Pellicori, P. , Flockton, R., Kallvikbacka-Bennett, A., Khan, J., Rigby, A. S., Girerd, N., Zannad, F., Cleland, J. G.F. and Clark, A. L. (2021) The prevalence and clinical associations of ultrasound measures of congestion in patients at risk of developing heart failure. European Journal of Heart Failure, 23(11), pp. 1831-1840. (doi: 10.1002/ejhf.2353) (PMID:34632680)

Jani, B. D. et al. (2021) Family history of diabetes and risk of SARS-COV-2 in UK Biobank: a prospective cohort study. Endocrinology, Diabetes and Metabolism, 4(4), e00283. (doi: 10.1002/edm2.283) (PMID:34505416) (PMCID:PMC8420405)

Rankin, A. J. et al. (2021) Global longitudinal strain by feature tracking cardiovascular MRI predicts mortality in patients with end stage kidney disease. Clinical Kidney Journal, 14(10), pp. 2187-2196. (doi: 10.1093/ckj/sfab020)

Al-Ozairi, E. et al. (2021) Risk of mortality among inpatients with COVID-19 and type 2 diabetes: national data from Kuwait. Endocrinology, Diabetes and Metabolism, 4(4), e00287. (doi: 10.1002/edm2.287) (PMID:34505420) (PMCID:PMC8420596)

Touyz, R. M. et al. (2021) Cardiovascular and renal risk factors and complications associated with COVID-19. CJC Open, 3(10), pp. 1257-1272. (doi: 10.1016/j.cjco.2021.05.020) (PMID:34151246) (PMCID:PMC8205551)

Ho, F. K., Man, K. K.S., Toshner, M., Church, C., Celis-Morales, C. , Wong, I. C.K., Berry, C. , Sattar, N. and Pell, J. P. (2021) Thromboembolic risk in hospitalised and non-hospitalised Covid-19 patients: a self-controlled case series analysis of a nation-wide cohort. Mayo Clinic Proceedings, 96(10), pp. 2587-2597. (doi: 10.1016/j.mayocp.2021.07.002) (PMID:34607634) (PMCID:PMC8282478)

Adamson, C. et al. (2021) Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. European Journal of Heart Failure, 23(10), pp. 1662-1672. (doi: 10.1002/ejhf.2308) (PMID:34272791)

Sattar, N. et al. (2021) Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes and Endocrinology, 9(10), pp. 653-662. (doi: 10.1016/S2213-8587(21)00203-5) (PMID:34425083)

Jackson, A. M. et al. (2021) Sacubitril–valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. European Heart Journal, 42(36), pp. 3741-3752. (doi: 10.1093/eurheartj/ehab499) (PMID:34392331) (PMCID:PMC8455346)

Curtain, J. P. et al. (2021) Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. European Heart Journal, 42(36), pp. 3727-3738. (doi: 10.1093/eurheartj/ehab560) (PMID:34448003) (PMCID:PMC8455345)

Pellicori, P. and Cleland, J. G.F. (2021) Structural heart disease, cardiac dysfunction and heart failure: the ambiguity of a definition. European Journal of Preventive Cardiology, 28(9), pp. 921-923. (doi: 10.1177/2047487320937135) (PMID:32718235)

Alves-Lopes, R. et al. (2021) Selective inhibition of the C-domain of ACE (angiotensin-converting enzyme) combined with inhibition of NEP (neprilysin): a potential new therapy for hypertension. Hypertension, 78(3), pp. 604-616. (doi: 10.1161/HYPERTENSIONAHA.121.17041) (PMID:34304582) (PMCID:PMC8357049)

Docherty, N. G., Delles, C. , D’Haese, P., Layton, A. T., Martínez-Salgado, C., Vervaet, B. A. and López-Hernández, F. J. (2021) Haemodynamic frailty – A risk factor for acute kidney injury in the elderly. Ageing Research Reviews, 70, 101408. (doi: 10.1016/j.arr.2021.101408) (PMID:34271185)

Romaszko, L., Borowska, A. , Lazarus, A., Dalton, D., Berry, C. , Luo, X. , Husmeier, D. and Gao, H. (2021) Neural network-based left ventricle geometry prediction from CMR images with application in biomechanics. Artificial Intelligence In Medicine, 119, 102140. (doi: 10.1016/j.artmed.2021.102140)

Heggie, R. et al. (2021) Stratified medicine using invasive coronary function testing in angina: a cost-effectiveness analysis of the British Heart Foundation CorMicA trial. International Journal of Cardiology, 337, pp. 44-51. (doi: 10.1016/j.ijcard.2021.05.016) (PMID:33992700)

Rossitto, G. and Delles, C. (2021) Mechanisms of sodium-mediated injury in cardiovascular disease: old play, new scripts. FEBS Journal, (doi: 10.1111/febs.16155) (PMID:34355504) (Early Online Publication)

Boder, P., Mary, S. , Mark, P. B. , Leiper, J. , Dominiczak, A. F. , Padmanabhan, S. , Rampold, L. and Delles, C. (2021) Mechanistic interactions of uromodulin with the thick ascending limb: perspectives in physiology and hypertension. Journal of Hypertension, 39(8), pp. 1490-1504. (doi: 10.1097/HJH.0000000000002861) (PMID:34187999) (PMCID:PMC7611110)

Ambrosy, A. P., von Haehling, S., Kalra, P. R., Court, E., Bhandari, S., McDonagh, T. and Cleland, J. G.F. (2021) Safety and efficacy of intravenous ferric derisomaltose compared to iron sucrose for iron deficiency anemia in patients with chronic kidney disease with and without heart failure. American Journal of Cardiology, 152, pp. 138-145. (doi: 10.1016/j.amjcard.2021.04.042) (PMID:34162484)

Petrie, M. C. , Lee, M. M.Y. and Docherty, K. F. (2021) Sodium–glucose co-transporter 2 inhibitors—the first successful treatment for heart failure with preserved ejection fraction? European Journal of Heart Failure, 23(8), pp. 1256-1259. (doi: 10.1002/ejhf.2108) (PMID:33502794)

Graham, F. J., Pellicori, P. , Ford, I. , Petrie, M. C. , Kalra, P. R. and Cleland, J. G.F. (2021) Intravenous iron for heart failure with evidence of iron deficiency: a meta-analysis of randomised trials. Clinical Research in Cardiology, 110(8), pp. 1299-1307. (doi: 10.1007/s00392-021-01837-8) (PMID:33755777)

Lees, J. S. et al. (2021) Kidney function and cancer risk: an analysis using creatinine and cystatin C in a cohort study. EClinicalMedicine, 38, 101030. (doi: 10.1016/j.eclinm.2021.101030) (PMID:34505030)

Wamil, M., Coleman, R. L., Adler, A. I., McMurray, J. J.V. and Holman, R. R. (2021) Increased risk of incident heart failure and death is associated with insulin resistance in people with newly diagnosed type 2 diabetes: UKPDS 89. Diabetes Care, 44(8), pp. 1877-1884. (doi: 10.2337/dc21-0429) (PMID:34162666)

Docherty, K. F. et al. (2021) The effect of neprilysin inhibition on left ventricular remodeling in patients with asymptomatic left ventricular systolic dysfunction late after myocardial infarction. Circulation, 144(3), pp. 199-209. (doi: 10.1161/CIRCULATIONAHA.121.054892) (PMID:33983794)

Lee, M. M.Y. , McMurray, J. J.V. , Jhund, P. S. , Petrie, M. C. and Sattar, N. (2021) Response by Lee et al to letter regarding article, "Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)". Circulation, 144(3), e40. (doi: 10.1161/CIRCULATIONAHA.121.055067) (PMID:34279995)

Halliday, B. P. et al. (2021) Heart rate as a marker of relapse during withdrawal of therapy in recovered dilated cardiomyopathy. JACC: Heart Failure, 9(7), pp. 509-517. (doi: 10.1016/j.jchf.2021.03.010) (PMID:34119469) (PMCID:PMC8259664)

Gök, C. , Main, A., Gao, X., Kerekes, Z., Plain, F., Kuo, C.-W., Robertson, A. D., Fraser, N. J. and Fuller, W. (2021) Insights into the molecular basis of the palmitoylation and depalmitoylation of NCX1. Cell Calcium, 97, 102408. (doi: 10.1016/j.ceca.2021.102408) (PMID:33873072)

Pellicori, P. et al. (2021) Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA-REG OUTCOME trial. European Journal of Heart Failure, 23(7), pp. 1085-1093. (doi: 10.1002/ejhf.2220) (PMID:34031968)

Jhund, P. S. et al. (2021) Heart failure hospitalization in adults receiving maintenance hemodialysis and effect of intravenous iron therapy: A report from PIVOTAL. JACC: Heart Failure, 9(7), pp. 518-527. (doi: 10.1016/j.jchf.2021.04.005) (PMID:34119470)

Cleland, J. G.F. et al. (2021) The struggle towards a universal definition of heart failure—how to proceed? European Heart Journal, 42(24), pp. 2331-2343. (doi: 10.1093/eurheartj/ehab082) (PMID:33791787)

Anand, A. et al. (2021) High-sensitivity cardiac troponin on presentation to rule out myocardial infarction: a stepped-wedge cluster randomized controlled trial. Circulation, 143(23), pp. 2214-2224. (doi: 10.1161/CIRCULATIONAHA.120.052380) (PMID:33752439) (PMCID:PMC8177493)

Maznyczka, A. M. et al. (2021) Thermodilution-derived temperature recovery time, a novel predictor of microvascular reperfusion and prognosis after myocardial infarction. EuroIntervention, 17(3), pp. 220-228. (doi: 10.4244/EIJ-D-19-00904) (PMID:32122822)

Murray, E. , Rossitto, G. and Delles, C. (2021) Haemodynamic assessment in hypertension: the soloists and the orchestra. Journal of Hypertension, 39(6), pp. 1109-1111. (doi: 10.1097/HJH.0000000000002796) (PMID:33967215)

Butt, J. H. et al. (2021) Efficacy and safety of dapagliflozin in men and women with heart failure with reduced ejection fraction: results from the DAPA-HF trial. JAMA Cardiology, 6(6), pp. 678-689. (doi: 10.1001/jamacardio.2021.0379) (PMID:33787831)

Mary, S. , Small, H., Herse, F., Carrick, E., Flynn, A., Mullen, W. , Dechend, R. and Delles, C. (2021) Pre-existing hypertension and pregnancy induced hypertension reveal molecular differences in placental proteome in rodents. Physiological Genomics, 53(6), pp. 259-268. (doi: 10.1152/physiolgenomics.00160.2020) (PMID:33969702)

Jhund, P. S. et al. (2021) Dapagliflozin and recurrent heart failure hospitalizations in heart failure with reduced ejection fraction: an analysis of DAPA-HF. Circulation, 143(20), pp. 1962-1972. (doi: 10.1161/CIRCULATIONAHA.121.053659) (PMID:33832352) (PMCID:PMC8126492)

Rossitto, G. et al. (2021) High sodium intake, glomerular hyperfiltration and protein catabolism in patients with essential hypertension. Cardiovascular Research, 117(5), pp. 1372-1381. (doi: 10.1093/cvr/cvaa205) (PMID:33053160) (PMCID:PMC8064429)

Lee, M. M.Y. , Ghouri, N. , McGuire, D. K., Rutter, M. K. and Sattar, N. (2021) Meta-analyses of results from randomized outcome trials comparing cardiovascular effects of SGLT2i and GLP-1RA in Asian vs. White patients with and without type 2 diabetes. Diabetes Care, 44(5), pp. 1236-1241. (doi: 10.2337/dc20-3007) (PMID:33707305)

Connelly, P. J. , Azizi, Z., Alipour, P., Delles, C. , Pilote, L. and Raparelli, V. (2021) The importance of gender to understand sex differences in cardiovascular disease. Canadian Journal of Cardiology, 37(5), pp. 699-710. (doi: 10.1016/j.cjca.2021.02.005) (PMID:33592281)

Ferreira, J. P. et al. (2021) Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial. European Journal of Heart Failure, 23(5), pp. 776-784. (doi: 10.1002/ejhf.2134) (PMID:33609066)

Shen, L. et al. (2021) Incidence and outcomes of pneumonia in patients with heart failure. Journal of the American College of Cardiology, 77(16), pp. 1961-1973. (doi: 10.1016/j.jacc.2021.03.001) (PMID:33888245)

Sattar, N. and Forouhi, N. G. (2021) More evidence for 5-a-day for fruit and vegetables and a greater need for translating dietary research evidence to practice. Circulation, 143(17), pp. 1655-1658. (doi: 10.1161/CIRCULATIONAHA.121.053293) (PMID:33900834)

Höskuldsdóttir, G., Sattar, N. , Miftaraj, M., Näslund, I., Ottosson, J., Franzén, S., Svensson, A.-M. and Eliasson, B. (2021) Potential effects of bariatric surgery on the incidence of heart failure and atrial fibrillation in patients with type 2 diabetes mellitus and obesity and on mortality in patients with preexisting heart failure: a nationwide, matched, observational cohort study. Journal of the American Heart Association, 10(7), e019323. (doi: 10.1161/JAHA.120.019323) (PMID:33754795) (PMCID:PMC8174344)

Touyz, R. M. and Schiffrin, E. L. (2021) A compendium on hypertension: new advances and future impact. Circulation Research, 128(7), pp. 803-807. (doi: 10.1161/CIRCRESAHA.121.319181) (PMID:33793329)

Griendling, K. K., Camargo, L. L., Rios, F. , Alves-Lopes, R., Montezano, A. C. and Touyz, R. M. (2021) Oxidative stress and hypertension. Circulation Research, 128(7), pp. 993-1020. (doi: 10.1161/CIRCRESAHA.121.318063) (PMID:33793335)

Dewan, P. et al. (2021) Effects of dapagliflozin in heart failure with reduced ejection fraction, and chronic obstructive pulmonary disease: an analysis of DAPA-HF. European Journal of Heart Failure, 23(4), pp. 632-643. (doi: 10.1002/ejhf.2083) (PMID:33368858) (PMCID:PMC8247863)

van Dorst, D. C.H., Dobbin, S. J.H. , Neves, K. B. , Herrmann, J., Herrmann, S. M., Versmissen, J., Mathijssen, R. H.J., Danser, A.H. J. and Lang, N. N. (2021) Hypertension and prohypertensive antineoplastic therapies in cancer patients. Circulation Research, 128(7), pp. 1040-1061. (doi: 10.1161/CIRCRESAHA.121.318051) (PMID:33793337) (PMCID:PMC8011349)

Butt, J. H. et al. (2021) Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial. European Journal of Heart Failure, 23(4), pp. 601-613. (doi: 10.1002/ejhf.2124) (PMID:33594755)

Docherty, K. F. et al. (2021) Effect of dapagliflozin on anaemia in DAPA-HF. European Journal of Heart Failure, 23(4), pp. 617-628. (doi: 10.1002/ejhf.2132) (PMID:33615642)

Scott, K., Morgan, H. L., Delles, C. , Fisher, S., Graham, D. and McBride, M. W. (2021) Distinct uterine artery gene expression profiles during early gestation in the stroke-prone spontaneously hypertensive rat. Physiological Genomics, 53(4), pp. 160-171. (doi: 10.1152/physiolgenomics.00159.2020) (PMID:33719581)

Mooney, L., Goodyear, C. S. , Chandra, T., Kirshner, K., Copland, M. , Petrie, M. C. and Lang, N. N. (2021) Clonal haematopoiesis of indeterminate potential: intersections between inflammation, vascular disease and heart failure. Clinical Science, 135(7), pp. 991-1007. (doi: 10.1042/CS20200306) (PMID:33861346) (PMCID:PMC8055963)

Sigfrid, L. et al. (2021) What is the recovery rate and risk of long-term consequences following a diagnosis of COVID-19? A harmonised, global longitudinal observational study protocol. BMJ Open, 11(3), e043887. (doi: 10.1136/bmjopen-2020-043887) (PMID:33692181) (PMCID:PMC7948153)

Crouch, S. H., Botha-Le Roux, S., Delles, C. , Graham, L. A. and Schutte, A. E. (2021) Inflammation and salt in young adults: the African-PREDICT study. European Journal of Nutrition, 60(2), pp. 873-882. (doi: 10.1007/s00394-020-02292-3) (PMID:32494865) (PMCID:PMC7900065)

Sykes, R. A. , Mohamed, M. O., Kwok, C. S., Mamas, M. A. and Berry, C. (2021) Percutaneous coronary intervention and 30-day unplanned readmission with chest pain in the United States (nationwide readmissions database). Clinical Cardiology, 44(3), pp. 291-306. (doi: 10.1002/clc.23543) (PMID:33590937) (PMCID:PMC7943906)

Briscoe, M., Sykes, R. , Krystofiak, T., Peck, O., Mangion, K. and Berry, C. (2021) Clinical significance of coronavirus disease 2019 in hospitalized patients with myocardial injury. Clinical Cardiology, 44(3), pp. 332-339. (doi: 10.1002/clc.23530) (PMID:33501708) (PMCID:PMC7943910)

Pellicori, P. et al. (2021) COVID-19 and its cardiovascular effects: a systematic review of prevalence studies. Cochrane Database of Systematic Reviews, 2021(3), CD013879. (doi: 10.1002/14651858.CD013879) (PMID:33704775)

Neves, K. B. , Morris, H., Alves-Lopes, R., Muir, K. W. , Moreton, F., Delles, C. , Montezano, A. C. and Touyz, R. M. (2021) Peripheral arteriopathy caused by Notch3 gain-of-function mutation involves ER and oxidative stress and blunting of NO∕sGC∕cGMP pathway. Clinical Science, 135(6), pp. 753-773. (doi: 10.1042/CS20201412) (PMID:33681964)

Ehteshami-Afshar, S. et al. (2021) Clinical characteristics and outcomes of patients with heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: insights from PARADIGM-HF. Journal of the American Heart Association, 10(4), e019238. (doi: 10.1161/JAHA.120.019238) (PMID:33522249) (PMCID:PMC7955331)

Lee, M. M.Y. et al. (2021) Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation, 143(6), pp. 516-525. (doi: 10.1161/CIRCULATIONAHA.120.052186) (PMID:33186500) (PMCID:PMC7864599)

Petrie, M. C. , Lee, M. M. and Lang, N. N. (2021) EMPEROR-REDUCED reigns while EMPERIAL whimpers. European Heart Journal, 42(6), pp. 711-714. (doi: 10.1093/eurheartj/ehaa965) (PMID:33367572)

Connelly, P. J. , Clark, A., Touyz, R. M. and Delles, C. (2021) Transgender adults, gender-affirming hormone therapy and blood pressure: a systematic review. Journal of Hypertension, 39(2), pp. 223-230. (doi: 10.1097/HJH.0000000000002632) (PMID:32809982) (PMCID:PMC7810409)

Docherty, K. F. et al. (2021) Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling. ESC Heart Failure, 8(1), pp. 129-138. (doi: 10.1002/ehf2.13137) (PMID:33305513) (PMCID:PMC7835504)

Hastie, C. , Pell, J. and Sattar, N. (2021) Vitamin D and COVID-19 infection and mortality in UK Biobank. European Journal of Nutrition, 60, pp. 545-548. (doi: 10.1007/s00394-020-02372-4) (PMID:32851419) (PMCID:PMC7449523)

Maznyczka, A. M. et al. (2021) Risk stratification guided by the index of microcirculatory resistance and left ventricular end-diastolic pressure in acute myocardial infarction. Circulation: Cardiovascular Interventions, 14(2), e009529. (doi: 10.1161/CIRCINTERVENTIONS.120.009529) (PMID:33591821)

Maznyczka, A. M. et al. (2021) Effect of coronary flow on intracoronary alteplase: a prespecified analysis from a randomised trial. Heart, 107(4), pp. 299-312. (doi: 10.1136/heartjnl-2020-317828) (PMID:33436493)

Li, W., Gao, H. , Mangion, K., Berry, C. and Luo, X. (2021) Apparent growth tensor of left ventricular post myocardial infarction – in human first natural history study. Computers in Biology and Medicine, 129, 104168. (doi: 10.1016/j.compbiomed.2020.104168) (PMID:33341555)

Kuriakose, J., Montezano, A. C. and Touyz, R. M. (2021) ACE-2/Ang (1-7)/Mas axis and the vascular system: vasoprotection to COVID-19-associated vascular disease. Clinical Science, 135(2), pp. 387-407. (doi: 10.1042/CS20200480) (PMID:33511992) (PMCID:PMC7846970)

Jhund, P. S. et al. (2021) Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF. Circulation, 143(4), pp. 289-309. (doi: 10.1161/CIRCULATIONAHA.120.050391) (PMID:33040613) (PMCID:PMC7834909)

Willder, J. M., McCall, P. , Messow, C.-M. , Gillies, M., Berry, C. and Shelley, B. (2021) Study protocol for COVID-RV: a multicentre prospective observational cohort study of right ventricular dysfunction in ventilated patients with COVID-19. BMJ Open, 11(1), e042098. (doi: 10.1136/bmjopen-2020-042098) (PMID:33441361) (PMCID:PMC7811959)

Dobbin, S. J.H. , Petrie, M. C. , Myles, R. C. , Touyz, R. M. and Lang, N. N. (2021) Cardiotoxic effects of angiogenesis inhibitors. Clinical Science, 135(1), pp. 71-100. (doi: 10.1042/CS20200305) (PMID:33404052) (PMCID:PMC7812690)

McMurray, J. J.V. and Docherty, K. F. (2021) SOLOIST-WHF: Sodium-glucose cotransporter 2 (SGLT2) inhibitors should be initiated in patients hospitalised with worsening heart failure. European Journal of Heart Failure, 23(1), pp. 27-30. (doi: 10.1002/ejhf.2075) (PMID:33283384)

Boguslavskyi, A. et al. (2021) Phospholemman phosphorylation regulates vascular tone, blood pressure and hypertension in mice and man. Circulation, 143(11), pp. 1123-1138. (doi: 10.1161/CIRCULATIONAHA.119.040557) (PMID:33334125) (PMCID:PMC7969167)

Jacobs, M., Benovoy, M., Chang, L.-C., Corcoran, D., Berry, C. , Arai, A. E. and Hsu, L.-Y. (2021) Automated segmental analysis of fully quantitative myocardial blood flow maps by first-pass perfusion cardiovascular magnetic resonance. IEEE Access, 9, pp. 52796-52811. (doi: 10.1109/ACCESS.2021.3070320) (PMID:33996344) (PMCID:PMC8117952)

Sykes, R. , Briscoe, M., Krystofiak, T., Peck, O., Mangion, K. and Berry, C. (2021) Type 2 myocardial infarction and myocardial injury: eligibility for novel medical therapy to de-risk clinical trials. Open Heart, 8, e001633. (doi: 10.1136/openhrt-2021-001633) (PMID:34083388) (PMCID:PMC8174491)

Sykes, R. , Doherty, D., Mangion, K., Morrow, A. and Berry, C. (2021) What an interventionalist needs to know about MI with non-obstructive coronary arteries. Interventional Cardiology Review, 16, e10. (doi: 10.15420/icr.2021.10) (PMID:34188694) (PMCID:PMC8218171)

Anderson, J. J. et al. (2021) Ethnic differences in prevalence of actionable HbA1c levels in UK Biobank: implications for screening. BMJ Open Diabetes Research and Care, 9(1), e002176. (doi: 10.1136/bmjdrc-2021-002176) (PMID:34353880) (PMCID:PMC8344314)

McGettrick, M., MacLellan, A., McCaughey, P., Bagot, C., Brewis, M.J., Lang, N.N. , Johnson, M.K. and Church, A.C. (2021) Pulmonary thromboembolism in hospitalised patients with COVID-19: a retrospective national study of patients managed in critical care and ward environments in Scotland. BMJ Open, 11, e050281. (doi: 10.1136/bmjopen-2021-050281) (PMID:34462282)

Kamdar, A., Sykes, R. , Morrow, A. , Mangion, K. and Berry, C. (2021) Cardiovascular outcomes of glucose lowering therapy in chronic kidney disease patients: a systematic review with meta-analysis. Reviews in Cardiovascular Medicine, 22(4), pp. 1479-1490. (doi: 10.31083/j.rcm2204152) (PMID:34957787)

Rossitto, G. et al. (2020) Reduced lymphatic reserve in heart failure with preserved ejection fraction. Journal of the American College of Cardiology, 76(24), pp. 2817-2829. (doi: 10.1016/j.jacc.2020.10.022) (PMID:33303070) (PMCID:PMC7724570)

Kristensen, S. L. et al. (2020) Prevalence and incidence of intra-ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM‐HF and ATMOSPHERE. European Journal of Heart Failure, 22(12), pp. 2370-2379. (doi: 10.1002/ejhf.1972) (PMID:32720404)

Ferreira, J. P. et al. (2020) Estimating the lifetime benefits of treatments for heart failure. JACC: Heart Failure, 8(12), pp. 984-995. (doi: 10.1016/j.jchf.2020.08.004) (PMID:33039448) (PMCID:PMC7720789)

Pashova, A., Work, L.M. and Nicklin, S.A. (2020) The role of extracellular vesicles in neointima formation post vascular injury. Cellular Signalling, 76, 109783. (doi: 10.1016/j.cellsig.2020.109783) (PMID:32956789)

Main, A., Fuller, W. and Baillie, G. S. (2020) Post-translational regulation of cardiac myosin binding protein-C: a graphical review. Cellular Signalling, 76, 109788. (doi: 10.1016/j.cellsig.2020.109788) (PMID:32976931)

Yeoh, S. E. et al. (2020) Relationship between duration of heart failure, patient characteristics, outcomes, and effect of therapy in PARADIGM-HF. ESC Heart Failure, 7(6), pp. 3355-3364. (doi: 10.1002/ehf2.12972) (PMID:33078584) (PMCID:PMC7754973)

Angwin, C. et al. (2020) TriMaster: randomised double-blind crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as second-line or third-line therapy in patients with type 2 diabetes who have suboptimal glycaemic control on metformin treatment with or without a sulfonylurea—a MASTERMIND study protocol. BMJ Open, 10(12), e042784. (doi: 10.1136/bmjopen-2020-042784) (PMID:33371044) (PMCID:PMC7754630)

Ho, F. K. et al. (2020) Modifiable and non-modifiable risk factors for COVID-19, and comparison to risk factors for influenza and pneumonia: results from a UK Biobank prospective cohort study. BMJ Open, 10, e040402. (doi: 10.1136/bmjopen-2020-040402) (PMID:33444201) (PMCID:PMC7678347)

Dewan, P. et al. (2020) The prevalence and importance of frailty in heart failure with reduced ejection fraction – an analysis of PARADIGM-HF and ATMOSPHERE. European Journal of Heart Failure, 22(11), pp. 2123-2133. (doi: 10.1002/ejhf.1832) (PMID:32353205)

Morrow, A. J. et al. (2020) Rationale and design of the Medical Research Council precision medicine with Zibotentan in microvascular angina (PRIZE) trial. American Heart Journal, 229, pp. 70-80. (doi: 10.1016/j.ahj.2020.07.007) (PMID:32942043)

Charla, E., Mercer, J. , Maffia, P. and Nicklin, S. (2020) Extracellular vesicle signalling in atherosclerosis. Cellular Signalling, 75, 109751. (doi: 10.1016/j.cellsig.2020.109751) (PMID:32860954) (PMCID:PMC7534042)

Ferreira, J. P., Mogensen, U. M., Jhund, P. S. , Desai, A. S., Zile, M. R., Rossignol, P., Zannad, F., Packer, M., Solomon, S. D. and McMurray, J. J.V. (2020) Serum potassium in the PARADIGM-HF trial. European Journal of Heart Failure, 22(11), pp. 2056-2064. (doi: 10.1002/ejhf.1987) (PMID:32809261) (PMCID:PMC7756204)

Docherty, K. et al. (2020) Effect of dapagliflozin in DAPA-HF according to background glucose-lowering therapy. Diabetes Care, 43(11), pp. 2878-2881. (doi: 10.2337/dc20-1402) (PMID:33082245)

Docherty, K. F. et al. (2020) Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction: a prespecified analysis of DAPA-HF. Circulation, 142(17), pp. 1623-1632. (doi: 10.1161/CIRCULATIONAHA.120.047480) (PMID:32883108) (PMCID:PMC7580857)

Lang, N. N. , Dobbin, S. J.H. and Petrie, M. C. (2020) Vericiguat in worsening heart failure – agonising over, or celebrating, agonism. Cardiovascular Research, 116(12), e152-e155. (doi: 10.1093/cvr/cvaa247) (PMID:32980877)

Dewan, P. , Jhund, P. S. and McMurray, J. J.V. (2020) VICTORIA in context. European Journal of Heart Failure, 22(10), pp. 1747-1751. (doi: 10.1002/ejhf.1833) (PMID:32363731)

Martinez-Amezcua, P. et al. (2020) The upcoming epidemic of heart failure in South Asia. Circulation: Heart Failure, 13(10), e007218. (doi: 10.1161/CIRCHEARTFAILURE.120.007218) (PMID:32962410)

Serenelli, M. et al. (2020) Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). European Heart Journal, 41(36), pp. 3402-3418. (doi: 10.1093/eurheartj/ehaa496) (PMID:32820334) (PMCID:PMC7550197)

Jackson, A. M. et al. (2020) Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF. Circulation, 142(11), pp. 1040-1054. (doi: 10.1161/CIRCULATIONAHA.120.047077) (PMID:32673497) (PMCID:PMC7664959)

Cameron, A. C. et al. (2020) Comprehensive characterisation of the vascular effects of cisplatin-based chemotherapy in patients with testicular cancer. JACC: CardioOncology, 2(3), pp. 443-455. (doi: 10.1016/j.jaccao.2020.06.004) (PMID:33043304) (PMCID:PMC7539369)

Sattar, N. et al. (2020) BMI and future risk for COVID-19 infection and death across sex, age and ethnicity: preliminary findings from UK biobank. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 14(5), pp. 1149-1151. (doi: 10.1016/j.dsx.2020.06.060) (PMID:32668401) (PMCID:PMC7326434)

Ford, T. J. et al. (2020) Assessment of vascular dysfunction in patients without obstructive coronary artery disease: why, how and when. JACC: Cardiovascular Interventions, 13(16), pp. 1847-1864. (doi: 10.1016/j.jcin.2020.05.052) (PMID:32819476) (PMCID:PMC7447977)

Rossitto, G. et al. (2020) Tissue sodium excess is not hypertonic and reflects extracellular volume expansion. Nature Communications, 11, 4222. (doi: 10.1038/s41467-020-17820-2) (PMID:32839436) (PMCID:PMC7445299)

McClure, J. D. , Ramsay, J. C. and Berry, C. (2020) Pooled analysis of bleeding and major adverse cardiovascular events in clinical trials of time-constrained dual-antiplatelet therapy after percutaneous coronary intervention. Journal of the American Heart Association, 9(16), e017109. (doi: 10.1161/JAHA.120.017109) (PMID:32779497) (PMCID:PMC7660822)

Guzik, T. J. et al. (2020) COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovascular Research, 116(10), pp. 1666-1687. (doi: 10.1093/cvr/cvaa106) (PMID:32352535) (PMCID:PMC7197627)

Campbell, R. T. et al. (2020) The novel urinary proteomic classifier HF1 has similar diagnostic and prognostic utility to BNP in heart failure. ESC Heart Failure, 7(4), pp. 1595-1604. (doi: 10.1002/ehf2.12708) (PMID:32383555) (PMCID:PMC7373887)

Dobbie, L. J., Mackin, S. T., Hogarth, K., Lonergan, F., Kannenkeril, D., Brooksbank, K. and Delles, C. (2020) Validation of semi-automated flow mediated dilation measurement in healthy volunteers. Blood Pressure Monitoring, 25(4), pp. 216-223. (doi: 10.1097/MBP.0000000000000448) (PMID:32304385) (PMCID:PMC7331823)

Zou, Z.-G. et al. (2020) Epidermal growth factor signaling through transient receptor potential melastatin 7 cation channel regulates vascular smooth muscle cell function. Clinical Science, 134(15), pp. 2019-2035. (doi: 10.1042/CS20200827) (PMID:32706027) (PMCID:PMC8299307)

Connelly, P. J. , Jandeleit-Dahm, K. A.M. and Delles, C. (2020) Sex and gender aspects in vascular pathophysiology. Clinical Science, 134(16), pp. 2203-2207. (doi: 10.1042/CS20200876) (PMID:32844996)

Bulluck, H. et al. (2020) Redefining adverse and reverse left ventricular remodeling by cardiovascular magnetic resonance following ST-segment elevation myocardial infarction and their implications on long-term prognosis. Circulation: Cardiovascular Imaging, 13(7), e009937. (doi: 10.1161/CIRCIMAGING.119.009937) (PMID:32689822)

Fong, L. C. W., Ford, T. J. , da Costa, B. R., Jüni, P. and Berry, C. (2020) Bias and loss to follow-up in cardiovascular randomized trials: a systematic review. Journal of the American Heart Association, 9(14), e015361. (doi: 10.1161/JAHA.119.015361) (PMID:32646264) (PMCID:PMC7660731)

Louca, P., Mompeo, O., Leeming, E. R., Berry, S. E., Mangino, M., Spector, T. D., Padmanabhan, S. and Menni, C. (2020) Dietary influence on systolic and diastolic blood pressure in the TwinsUK cohort. Nutrients, 12(7), 2130. (doi: 10.3390/nu12072130) (PMID:32708992) (PMCID:PMC7400881)

Docherty, K. F. et al. (2020) Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. European Heart Journal, 41(25), pp. 2379-2392. (doi: 10.1093/eurheartj/ehaa183) (PMID:32221582) (PMCID:PMC7327533)

Dobbin, S. J.H. et al. (2020) Cardiotoxicity and myocardial hypoperfusion associated with anti-VEGF therapies: prospective cardiac magnetic resonance imaging in patients with cancer. European Journal of Heart Failure, 22(7), pp. 1276-1277. (doi: 10.1002/ejhf.1847) (PMID:32379945)

Hastie, C. E. et al. (2020) Vitamin D concentrations and COVID-19 infection in UK Biobank. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 14(4), pp. 561-565. (doi: 10.1016/j.dsx.2020.04.050) (PMID:32413819) (PMCID:PMC7204679)

Sattar, N. , McInnes, I. B. and McMurray, J. J.V. (2020) Obesity a risk factor for severe COVID-19 infection: multiple potential mechanisms. Circulation, 142(1), pp. 4-6. (doi: 10.1161/CIRCULATIONAHA.120.047659) (PMID:32320270)

Dewan, P. et al. (2020) Efficacy and safety of sodium–glucose co‐transporter 2 inhibition according to left ventricular ejection fraction in DAPA‐HF. European Journal of Heart Failure, 22(7), pp. 1247-1258. (doi: 10.1002/ejhf.1867) (PMID:32539224)

Cleland, J. G.F. , Li, C. and Jones, Y. (2020) Artificial intelligence needs clinical intelligence to succeed. JACC: Heart Failure, 8(7), pp. 588-591. (doi: 10.1016/j.jchf.2020.06.002) (PMID:32616167)

Cleland, J. G.F. , Lyon, A. R., McDonagh, T. and McMurray, J. J.V. (2020) The year in cardiology 2019: heart failure. Romanian Journal of Cardiology, 30(2), pp. 185-204. (doi: 10.47803/rjc.2020.30.2.185)

Al-Hussaini, A. et al. (2020) Chronic infarct size after spontaneous coronary artery dissection: implications for pathophysiology and clinical management. European Heart Journal, 41(23), pp. 2197-2205. (doi: 10.1093/eurheartj/ehz895) (PMID:31898721) (PMCID:PMC7299635)

Gök, C. , Plain, F., Robertson, A., Howie, J., Baillie, G. S. , Fraser, N. J. and Fuller, W. (2020) Dynamic palmitoylation of the sodium-calcium exchanger modulates its structure, affinity for lipid ordered domains, and inhibition by XIP. Cell Reports, 31(10), 107697. (doi: 10.1016/j.celrep.2020.107697) (PMID:32521252) (PMCID:PMC7296346)

Brainin, P. et al. (2020) Body mass index and B-lines on lung ultrasonography in chronic and acute heart failure. ESC Heart Failure, 7(3), pp. 1201-1209. (doi: 10.1002/ehf2.12640) (PMID:32077268) (PMCID:PMC7261588)

Picone, D. S. et al. (2020) Nonvalidated home blood pressure devices dominate the online marketplace in Australia: major implications for cardiovascular risk management. Hypertension, 75(6), pp. 1593-1599. (doi: 10.1161/hypertensionaha.120.14719) (PMID:32275193)

Touyz, R. M. , Feldman, R. D., Harrison, D. G. and Schiffrin, E. L. (2020) A new look at the mosaic theory of hypertension. Canadian Journal of Cardiology, 36(5), pp. 591-592. (doi: 10.1016/j.cjca.2020.03.025) (PMID:32389334)

Lip, S. and Padmanabhan, S. (2020) Genomics of blood pressure and hypertension: extending the mosaic theory toward stratification. Canadian Journal of Cardiology, 36(5), pp. 694-705. (doi: 10.1016/j.cjca.2020.03.001) (PMID:32389342) (PMCID:PMC7237883)

Delles, C. and Olfert, M. (2020) Electronic cigarettes: how bad are they for your health? Cardiovascular Research, 116(6), e64-e66. (doi: 10.1093/cvr/cvaa041) (PMID:32157289)

Touyz, R. , Rios, F. , Alves-Lopes, R., Neves, K. B. , De Lucca Camargo, L. and Montezano, A. C. (2020) Oxidative stress: a unifying paradigm in hypertension. Canadian Journal of Cardiology, 36, pp. 659-670. (doi: 10.1016/j.cjca.2020.02.081) (PMID:32389339) (PMCID:PMC7225748)

Maznyczka, A. M. et al. (2020) Comparative significance of invasive measures of microvascular injury in acute myocardial infarction. Circulation: Cardiovascular Interventions, 13(5), e008505. (doi: 10.1161/CIRCINTERVENTIONS.119.008505) (PMID:32408817) (PMCID:PMC7237023)

Petrie, M. C., et al. (2020) Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA: Journal of the American Medical Association, 323(14), pp. 1353-1368. (doi: 10.1001/jama.2020.1906) (PMID:32219386) (PMCID:PMC7157181)

Delles, C. , Li, H. and Touyz, R. M. (2020) ACE2 the Janus-faced protein – from cardiovascular protection to severe acute respiratory syndrome-coronavirus and COVID-19. Clinical Science, 134(7), pp. 747-750. (doi: 10.1042/CS20200363)

Cleland, J. G.F. , Lyon, A. R., McDonagh, T. and McMurray, J. J.V. (2020) The year in cardiology: heart failure. European Heart Journal, 41(12), pp. 1232-1248. (doi: 10.1093/eurheartj/ehz949) (PMID:31901936) (PMCID:PMC7084174)

Berry, C. and Duncker, D. J. (2020) Coronary microvascular disease: the next frontier for Cardiovascular Research. Cardiovascular Research, 116(4), pp. 737-740. (doi: 10.1093/cvr/cvaa035) (PMID:32149331) (PMCID:PMC7061275)

Sattar, N. , Gill, J. M.R. and Alazawi, W. (2020) Improving prevention strategies for cardiometabolic disease. Nature Medicine, 26(3), pp. 320-325. (doi: 10.1038/s41591-020-0786-7) (PMID:32152584)

Serenelli, M. et al. (2020) Mineralocorticoid receptor antagonists, blood pressure, and outcomes in heart failure with reduced ejection fraction. JACC: Heart Failure, 8(3), pp. 188-198. (doi: 10.1016/j.jchf.2019.09.011) (PMID:31926854) (PMCID:PMC7086149)

Rorth, R. et al. (2020) Comparison of BNP and NT-proBNP in patients with heart failure and reduced ejection fraction. Circulation: Heart Failure, 13(2), e006541. (doi: 10.1161/CIRCHEARTFAILURE.119.006541) (PMID:32065760)

McMurray, J. J.V. et al. (2020) Effects of Sacubitril-Valsartan, versus Valsartan, in Women Compared to Men with Heart Failure and Preserved Ejection Fraction: Insights from PARAGON-HF. Circulation, 141(5), pp. 338-351. (doi: 10.1161/CIRCULATIONAHA.119.044491) (PMID:31736337)

Crouch, S. H., Botha-Le Roux, S., Delles, C. , Graham, L. A. and Schutte, A. E. (2020) Distinct inflammatory mediator patterns in young black and white adults: The African-PREDICT study. Cytokine, 126, 154894. (doi: 10.1016/j.cyto.2019.154894)

Maznyczka, A. M. et al. (2020) One-year outcomes after low-dose intracoronary alteplase during primary percutaneous coronary intervention. The T-TIME randomized trial. Circulation: Cardiovascular Interventions, 13(2), e008855. (doi: 10.1161/CIRCINTERVENTIONS.119.008855) (PMID:32069113)

Welsh, C. et al. (2020) Glycated hemoglobin, prediabetes and the links to cardiovascular disease: data from UK Biobank. Diabetes Care, 43(2), pp. 440-445. (doi: 10.2337/dc19-1683) (PMID:31852727)

Martinez, F. A. et al. (2020) Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to age: insights from DAPA-HF. Circulation, 141(2), pp. 100-111. (doi: 10.1161/CIRCULATIONAHA.119.044133) (PMID:31736328)

Chapman, A. R. et al. (2020) High-sensitivity cardiac troponin and the universal definition of myocardial infarction. Circulation, 141(3), pp. 161-171. (doi: 10.1161/CIRCULATIONAHA.119.042960) (PMID:31587565) (PMCID:PMC6970546)

Coll, A. P. et al. (2020) GDF15 mediates the effects of metformin on body weight and energy balance. Nature, 578, pp. 444-448. (doi: 10.1038/s41586-019-1911-y) (PMID:31875646) (PMCID:PMC7234839)

Robertson, J., Lindgren, M., Schaufelberger, M., Adiels, M., Björck, L., Lundberg, C. E., Sattar, N. , Rosengren, A. and Åberg, M. (2020) Body Mass Index in young women and risk of cardiomyopathy: a long-term follow-up study in Sweden. Circulation, 141(7), pp. 520-529. (doi: 10.1161/CIRCULATIONAHA.119.044056) (PMID:32065765) (PMCID:PMC7017947)

Kotecha, D. et al. (2019) Impact of renal impairment on beta-blocker efficacy in patients with heart failure. Journal of the American College of Cardiology, 74(23), pp. 2893-2904. (doi: 10.1016/j.jacc.2019.09.059) (PMID:31806133)

Dewan, P. et al. (2019) Sex-related differences in heart failure with preserved ejection fraction. Circulation: Heart Failure, 12(12), e006539. (doi: 10.1161/CIRCHEARTFAILURE.119.006539) (PMID:31813280)

Neves, K. B. et al. (2019) ER stress and Rho kinase activation underlie the vasculopathy of CADASIL. JCI Insight, 4(23), e131344. (doi: 10.1172/jci.insight.131344) (PMID:31647781) (PMCID:PMC6962020)

Cameron, A. C. et al. (2019) Progressive hypertension and severe left ventricular outflow tract obstruction. Hypertension, 74(6), pp. 1216-1225. (doi: 10.1161/hypertensionaha.119.13343) (PMID:31587571)

Kristensen, S. L., Rorth, R., Jhund, P. S. , Docherty, K. , Sattar, N. , Preiss, D. , Kober, L., Petrie, M. C. and McMurray, J. J.V. (2019) Cardiovascular, mortality and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes and Endocrinology, 7(10), pp. 776-785. (doi: 10.1016/S2213-8587(19)30249-9) (PMID:31422062)

Shen, L. et al. (2019) Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction. European Journal of Heart Failure, 21(8), pp. 974-984. (doi: 10.1002/ejhf.1535) (PMID:31271255) (PMCID:PMC7079555)

Maznyczka, A. M., Oldroyd, K. G., McCartney, P., McEntegart, M. and Berry, C. (2019) The potential use of the index of microcirculatory resistance to guide stratification of patients for adjunctive therapy in acute myocardial infarction. JACC: Cardiovascular Interventions, 12(10), pp. 951-966. (doi: 10.1016/j.jcin.2019.01.246) (PMID:31122353)

This list was generated on Fri Nov 25 13:23:17 2022 GMT.

New Opportunities

Cardiovascular Oncology 

The cardiovascular-oncology theme in SCMH, initiated in 2018 and led by Prof Rhian Touyz and Dr Ninian Lang, focuses on the effects of cancer and its treatment upon cardiovascular disease. The aim is to minimise the competing risks of cardiovascular disease in patients with cancer. This theme is truly at the interface between cardiovascular medicine and cancer – at the research and clinical levels. The theme is a component of the strategic objectives of a British Heart Foundation (BHF) Centre of Excellence Award and is well supported by further specific research grants. 

Please see the main SCMH research pages for more detailed information on the Cardiovascular Oncology theme. 

Multi-morbidity and Chronic Diseases

COMING SOON